Origin and functional consequences of the complex I defect in Parkinson's disease

The mitochondrial electron transport enzyme NADH: ubiquinone oxidoreductase (complex I), which is encoded by both mitochondrial DNA and nuclear DNA, is defective in multiple tissues in persons with Parkinson's disease (PD). The origin of this lesion and its role in the neurodegeneration of PD are unknown. To address these questions, we created an in vitro system in which the potential contributions of environmental toxins, complex I nuclear DNA mutations, and mitochondrial DNA mutations could be systematically analyzed. A clonal line of human neuroblastoma cells containing no mitochondrial DNA was repopulated with mitochondria derived from the platelets of PD or control subjects. After 5 to 6 weeks in culture, these cytoplasmic hybrid (cybrid) cell lines were assayed for electron transport chain activities, production of reactive oxygen species, and sensitivity to induction of apoptotic cell death by 1‐methyl‐4‐phenyl pyridinium (MPP+). In PD cybrids we found a stable 20% decrement in complex I activity, increased oxygen radical production, and increased susceptibility to 1‐methyl‐4‐phenyl pyridinium‐induced programmed cell death. The complex I defect in PD appears to be genetic, arising from mitochondrial DNA, and may play an important role in the neurodegeneration of PD by fostering reactive oxygen species production and conferring increased neuronal susceptibility to mitochondrial toxins.

[1]  C. Filley,et al.  Cytochrome oxidase deficiency in Alzheimer's disease , 1990, Neurology.

[2]  J. Nobrega,et al.  Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.

[3]  M. King,et al.  Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. , 1989, Science.

[4]  J. Langston,et al.  Oxidation reactions in Parkinson's disease. Discussion , 1990 .

[5]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[6]  M. Quilliam,et al.  On auxotrophy for pyrimidines of respiration-deficient chick embryo cells. , 1984, European journal of biochemistry.

[7]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[8]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[9]  C. Ward,et al.  Parkinson's disease in 65 pairs of twins and in a set of quadruplets , 1983, Neurology.

[10]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[11]  J. Parks,et al.  Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. , 1994, Archives of biochemistry and biophysics.

[12]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[13]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[14]  David G. Nicholls,et al.  Bioenergetics an Introduction to the Chemiosmotic Theory , 1982 .

[15]  R. Mayeux,et al.  Does a long preclinical period occur in Parkinson's disease? , 1991, Neurology.

[16]  J. Bennett,et al.  Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. , 1994, Neuroreport.

[17]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[18]  D. A. Monte Mitochondrial DNA and Parkinson's disease , 1991 .

[19]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[20]  M. Runswick,et al.  Complementary DNA sequences of two 14.5 kDa subunits of NADH:ubiquinone oxidoreductase from bovine heart mitochondria Completion of the primary structure of the complex? , 1992, FEBS letters.

[21]  R. Ramsay,et al.  Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.

[22]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[23]  K. Stuhlmeier,et al.  A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescin-diacetate. , 1992, Journal of immunological methods.

[24]  M. Ratinaud,et al.  In situ flow cytometric analysis of nonyl acridine orange-stained mitochondria from splenocytes. , 1988, Cytometry.

[25]  J. Kaprio,et al.  Parkinson's disease in a nationwide twin cohort , 1988, Neurology.

[26]  M. Yahr,et al.  Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[27]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[28]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.

[29]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[30]  S. Horai,et al.  Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.

[31]  H. Misra,et al.  Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1993, The Journal of biological chemistry.

[32]  D. Johns Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. , 1995, The New England journal of medicine.

[33]  A Hofman,et al.  Prevalence of Parkinson's disease in the elderly , 1995, Neurology.

[34]  H. Weiss,et al.  De novo synthesis and desaturation of fatty acids at the mitochondrial acyl‐carrier protein, a subunit of NADH:ubiquinone oxidoreductase in Neurospora crassa , 1992, FEBS letters.

[35]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[36]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[37]  Eugene M. Johnson,et al.  Superoxide dismutase delays neuronal apoptosis: A role for reactive oxygen species in programmed neuronal death , 1995, Neuron.

[38]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[39]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[40]  R. Morais,et al.  Ethidium bromide-induced loss of mitochondrial DNA from primary chicken embryo fibroblasts , 1985, Molecular and cellular biology.

[41]  C. Marsden Parkinson's disease in twins. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[42]  L. Golbe The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.

[43]  E. Shoubridge,et al.  Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease , 1990, Cell.

[44]  T. Ozawa,et al.  Point mutations of mitochondrial genome in Parkinson's disease. , 1995, Brain research. Molecular brain research.

[45]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[46]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[47]  J. Hayashi,et al.  Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[49]  P. Desjardins,et al.  An established avian fibroblast cell line without mitochondrial DNA , 1986, Somatic cell and molecular genetics.

[50]  M. Beal,et al.  Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.